>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
脂蛋白(a)与慢性肾脏病患者心血管疾病研究进展
作者:林丽华1  刘宏1 2  刘必成1 2 
单位:1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学附属中大医院 肾内科, 江苏 南京 210009
关键词:脂蛋白(a) 慢性肾脏病 心血管疾病 综述 
分类号:R692
出版年·卷·期(页码):2017·36·第五期(852-855)
摘要:

慢性肾脏病(CKD)患病率不断上升,心血管疾病(CVD)是CKD患者的主要并发症及致死原因。脂蛋白(a)[Lp (a)]与普通人群CVD的患病率及死亡率相关,其与CKD患者CVD的相关性尚存在争议。本文作者主要就Lp (a)、CKD和CVD三者的相关性研究进展作一综述,为CKD患者CVD的临床诊断和治疗提供新思路。

参考文献:

[1] 汤涛涛,吕林莉,刘必成.microRNAs与肾脏纤维化[J].东南大学学报:医学版,2014,33(6):788-793.
[2] GAITA D,MIHAESCU A,SCHILLER A.Of heart and kidney:a complicated love story[J].Eur J Prev Cardiol,2014,21(7):840-846.
[3] HOOVER-PLOW J,HUANG M.Lipoprotein(a) metabolism:potential sites for therapeutic targets[J].Metabolism,2013,62(4):479-491.
[4] MARANHAO R C,CARVALHO P O,STRUNZ C C,et al.Lipoprotein (a):structure,pathophysiology and clinical implications[J].Arq Bras Cardiol,2014,103(1):76-84.
[5] KOLLERITS B,DRECHSLER C,KRANE V,et al.Lipoprotein(a) concentrations,apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus:results from the 4D Study[J].Nephrol Dial Transplant,2016,31(11):1901-1908.
[6] STEIN E A,RAAL F.Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease[J].Cardiovasc Drugs Ther,2016,30(1):101-108.
[7] BOFFA M B.Emerging therapeutic options for lowering of lipoprotein(a):implications for prevention of cardiovascular disease[J].Curr Atheroscler Rep,2016,18(12):69.
[8] van CAPELLEVEEN J C,van der VALK F M,STROES E S.Current therapies for lowering lipoprotein(a)[J].J Lipid Res,2015,57(9):1612-1618.
[9] KAMSTRUP P R,NORDESTGAARD B G.Lipoprotein(a) concentrations,isoform size,and risk of type 2 diabetes:a Mendelian randomisation study[J].Lancet Diabetes Endocrinol,2013,1(3):220-227.
[10] ZHU L,LU Z,ZHU L,et al.Plasma lipoprotein(a) levels are associated with the severity of coronaryheart disease in Han Chinese people[J].Turk J Med Sci,2016,46(4):1033-1041.
[11] FOGACCI F,CICERO A F,D'ADDATO S,et al.Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention:data from the Brisighella Heart Study[J].Eur J Intern Med,2017,37:49-55.
[12] NAVE A H,LANGE K S,LEONARDS C O,et al.Lipoprotein (a) as a risk factor for ischemic stroke:a meta-analysis[J].Atherosclerosis,2015,242(2):496-503.
[13] KOSTNER K M,KOSTNER G M.Lipoprotein(a):a historical appraisal[J].J Lipid Res,2017,58(1):1-14.
[14] WU H D,BERGLUND L,DIMAYUGA C,et al.High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort[J].J Am Coll Cardiol,2004,43(10):1828-1833.
[15] MANOCHA A,SRIVASTAVA L M.Lipoprotein (a):a unique independent risk factor for coronary artery disease[J].Indian J Clin Biochem,2016,31(1):13-20.
[16] OZAWA M,HIMAKI T,OOKUTSU S,et al.Production of cloned miniature pigs expressing high levels of human apolipoprotein(a) in plasma[J].PLoS One,2015,10(7):e0132155.
[17] AGGARWAL H K,JAIN D,LATHAR M,et al.Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease[J].Ren Fail,2010,32(6):647-652.
[18] LIN J,REILLY M P,TEREMBULA K,et al.Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria[J].PLoS One,2014,9(12):e114397.
[19] KHARRAT I,JMAL A,JMAL L,et al.Alterations in lipidic metabolism in hemodialysis patients[J].Tunis Med,2012,90(7):537-541.
[20] KAYSEN G A.The microinflammatory state in uremia:causes and potential consequences[J].J Am Soc Nephrol,2001,12(7):1549-1557.
[21] YUN J S,AHN Y B,SONG K H,et al.Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus[J].Diabet Med,2016,33(5):639-643.
[22] LIN J,KHETARPAL S A,TEREMBULA K,et al.Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline:a longitudinal study[J].BMC Nephrol,2015,16:130.
[23] KONISHI H,MIYAUCHI K,TSUBOI S,et al.Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention[J].Int J Cardiol,2016,205:50-53.
[24] LONGENECKER J C,KLAG M J,MARCOVINA S M,et al.High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients[J].J Am Soc Nephrol,2005,16(6):1794-1802.
[25] KRONENBERG F,NEYER U,LHOTTA K,et al.The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients:a prospective follow-up[J].J Am Soc Nephrol,1999,10(5):1027-1036.
[26] 黄文瑾,刘必成.维持性血液透析患者脂质代谢紊乱与心脑血管事件关系的临床研究[J].东南大学学报:医学版,2012,31(6):720-724.
[27] BOSSOLA M,TAZZA L,LUCIANI G,et al.OxPL/apoB,lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients[J].J Nephrol,2011,24(5):581-588.
[28] LONGENECKER J C,KLAG M J,MARCOVINA S M,et al.Small apolipoprotein(a) size predicts mortality in end-stage renal disease:the CHOICE study[J].Circulation,2002,106:2812-2818.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405592 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364